« Back
Home /
Recombinant Human Tumor necrosis factor receptor superfamily member 11B protein(TNFRSF11B) (Active)

Recombinant Human Tumor necrosis factor receptor superfamily member 11B protein(TNFRSF11B) (Active)

Item no.	CSB-AP003001HU-50
Manufacturer	Cusabio
Amount	50ug
Quantity options	1mg 10ug 100ug 250ug 50ug 500ug
Category	Oncology Peptides & Proteins Recombinant Proteins By Organ Lymphatic System Cancer
Type	Proteins Recombinant
Format	Lyophilized powder
Specific against	other
Host	E.coli
Purity	>95% as determined by SDS-PAGE and HPLC.
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	Osteoclastogenesis inhibitory factor,
Available
Classification	Cytokine
Subdivision	Tumor Necrosis Factor
Research Areas	Immunology
Uniprot NO.	O00300
Uniprot Entry Name	TR11B_HUMAN
Gene Names	TNFRSF11B, OCIF, OPG
Source	E.Coli
Expression Region	22-194aa
Sequence	ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QH CTAKWKTV CAPCPDHYYT DSWHTSDECL YCSP VCKELQ YVKQECNRTH NRVCECKEGR YLEIEF CLKH RSCPPGFGVV QAGTPERNTV CKRCPDGF FS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK
Protein Description	Partial
Tag Info	Tag-Free
Mol. Weight	19.7 kDa
Biological Activity	Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of ? 1.0 x 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL).
Purity	>95% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/ug as determined by LAL method.
Storage Buffer	0.2 um filtered 30 % acetonitrile, 0.1 % TFA , lyophilized
Alias	Osteoclastogenesis inhibitory factor,
Relevance	Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. {ECO:0000269\|PubMed:22664871, ECO:0000269\|PubMed:9168977}.
PubMed ID	9108485; 9492069; 9688283; 14702039; 16421571; 15489334; 9571159; 15340161; 12110935; 9168977; 9603945; 9478964; 11505389; 22664871; 12189164
Function	Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Involvement in disease	Paget disease of bone 5, juvenile-onset (PDB5)
Subcellular Location	Secreted
Tissue Specificity	Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Paythway	Osteoclastdifferentiation
Tag Information	Tag-Free

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

CSB-AP003001HU-50-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 50ug

available

Request delivery time